



### Product Description

Phoenix Pain is designed to manage chronic and acute pain through reduction in inflammation and provision of an analgesic effect. Pain management can be increased, simply by increasing the number of doses taken, unlike many current painkillers that have significantly higher risk profiles with increased dosing.

### Cannabinoid Extract Proprietor Compound

CANNABIDIOL (CBD), TETRAHYDRACANNABINOL (THC), CANNABINOL (CBN), AND OTHER TRACE CANNABINOIDS
B-CARYOPHYLLENE, P-CYMENE, B-PINENE, GERANIOL, TERPINOLENE

### Other Ingredients

Medium-chain triglycerides (MCT) derived from coconut, Water, Glycerin, Cannabis Extracts, Kolliphor HS-15, Peppermint Oil.

### Global Distribution Strategy

Phoenix Pain is classified as a specific formulation and dosing product that may be exempted or scheduled under a specific country regulations governing pharmaceuticals and drug control. The product must be produced, distributed and sold through licensed medical cannabis facilities and pharmaceutical distribution licensed to handle tetrahydrocannabinol. Distribution will be from Vanuatu and state to state US manufacturing.

<p><b>Online</b></p> <p>This product is classified as containing high amounts of "THC from Cannabis" and therefore can only be sold through licensed agencies. Phoenix Pain Online ordering provides for pick-up from a licensed distributor. Sold as Phoenix Pain (LE), without specific medical claims within the jurisdictions offered, unless otherwise approved.</p>	<p> <b>Australia</b></p> <p>Partner with local licensed producer for distribution under medical cannabis laws. Local clinical trials to be completed in 2022.</p>	<p> <b>Europe</b></p> <p>Partner with local licensed distributor under medical cannabis laws. Local clinical trials to be completed in 2024.</p>
<p><b>Global Distribution</b></p> <p>Now that 47 countries have legalized medical cannabis, the inter-country trade is starting to expand. Phoenix Life is focused on import and export of its products from company owned and partnered production facilities. Phoenix Pain can only be sold through licensed agencies through local production and export to over 40 countries.</p>	<p> <b>United States</b></p> <p>State to state distribution under product licensing agreement with Equaliti. Clinical trials to be commenced late 2023.</p>	<p> <b>Vanuatu</b></p> <p>May be supplied under Dr Approval. Local Supply expected in 2022.</p>

<p><b>Medical History and Development Information</b></p> <p>Initial Studies with a group of cannabis and non-cannabis users reported reduction in pain levels associated with large dose ibuprofen combined with an opioid. Dose models have been targeted to reduce acute pain and manage long term chronic pain. The product is designed to be sold in Soft Gel Capsules and Sub-lingual Sprays.</p>
---

<p><b>Clinical Stage</b></p> <p>INITIAL CANDIDATE STRAIN / FORMULATION SELECTED</p> <p>EFFICACY DATA COLLABORATED WITH RESEARCH TEAM</p> <p>INITIAL PATIENT GROUP SUCCESS</p> <p>LARGER PATIENT GROUP SUCCESS</p> <p>FORMALIZED CLINICAL TRIALS</p> <p>APPROVED FOR SALE IN LOCAL MARKET</p> <p>EXEMPTION AVAILABLE FOR IMMEDIATE SALES</p>
---

### Medical Evidence, Citations and other References

US National Library of Medicine - a part of the National Institutes of Health details the following study and abstract More details are available at <https://pubmed.ncbi.nlm.nih.gov/30152161/>  
 2018 Jul;58(7):1139-1186. DOI: 10.1111/head.13345 PMID: 30152161 Author: Eric P Baron

**Medicinal Properties of Cannabinoids, Terpenes, and Flavonoids in Cannabis, and Benefits in Migraine, Headache, and Pain: An Update on Current Evidence and Cannabis Science**  
 Abstract Background: Comprehensive literature reviews of historical perspectives and evidence supporting cannabis/cannabinoids in the treatment of pain, including migraine and headache, with associated neurobiological mechanisms of pain modulation have been well described. Most of the existing literature reports on the cannabinoids Δ9 -tetrahydrocannabinol (THC) and cannabidiol (CBD), or cannabis in general. There are many cannabis strains that vary widely in the composition of cannabinoids, terpenes, flavonoids, and other compounds. These components work synergistically to produce wide variations in benefits, side effects, and strain characteristics. Knowledge of the individual medicinal properties of the cannabinoids, terpenes, and flavonoids is necessary to cross-breed strains to obtain optimal standardized synergistic compositions. This will enable targeting individual symptoms and/or diseases, including migraine, headache, and pain. Conclusion: There is accumulating evidence for various therapeutic benefits of cannabis/cannabinoids, especially in the treatment of pain, which may also apply to the treatment of migraine and headache. There is also supporting evidence that cannabis may assist in opioid detoxification and weaning, thus making it a potential weapon in battling the opioid epidemic. Cannabis science is a rapidly evolving medical sector and industry with increasingly regulated production standards. Further research is anticipated to optimize breeding of strain-specific synergistic ratios of cannabinoids, terpenes, and other phytochemicals for predictable user effects, characteristics, and improved symptom and disease-targeted therapies.

LEGEND  Completed  Next Step  Not Completed